Vascular endothelial growth factor, or VEGF, is often targeted to prevent angiogenesis; When it is overexpressed, rapid tumour growth can result
Motesanib
A common target for anticancer agents is the prevention of angiogenesis. Vascular endothelial growth factor, or VEGF, is often targeted as it – and its receptors – plays such a pivotal role in the process. When it is overexpressed, rapid tumour growth can result.
Motesanib is another potential small molecule drug that acts as a VEGF receptor inhibitor, and is being developed by Takeda in partnership with Amgen.1 The orally available nicotinamide derivative has potential in a range of tumour types, and as well as its anti-VEGF activity at various receptors, it is an antagonist of platelet-derived growth factor receptors and the cellular stem cell factor, or Kit, receptor.
– See more at:
http://www.manufacturingchemist.com/technical/article_page/Anticancer_agent__motesanib/86732
